Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00077441
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00077428
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
PS-341 in Treating Patients With Metastatic Malignant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00024011
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
- Conditions
- Adult Acute Promyelocytic Leukemia (M3)Blastic Phase Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in TransformationRelapsing Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2004-02-02
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00005064
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 99
- Registration Number
- NCT00075751
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00075881
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Conditions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00074009
- Locations
- 🇺🇸
Queens Cancer Center of Queens Hospital, Jamaica, New York, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerStage III Bladder CancerStage III Urethral CancerStage IV Bladder CancerStage IV Urethral CancerTransitional Cell Carcinoma of the BladderUreter Cancer
- Interventions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00072150
- Locations
- 🇺🇸
UCSF-Mount Zion, San Francisco, California, United States
A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00068484
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Conditions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00068289
- Locations
- 🇺🇸
Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸Providence Cancer Institute at Providence Hospital, Southfield, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.